Maravai LifeSciences Holdings Inc (NAS:MRVI)
$ 5.67 -0.25 (-4.22%) Market Cap: 804.25 Mil Enterprise Value: 787.17 Mil PE Ratio: 0 PB Ratio: 2.33 GF Score: 73/100

Maravai LifeSciences Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 01:20PM GMT
Release Date Price: $23.36 (+1.88%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hey, everyone. My name is Tejas Savant, I'm the Life Sciences Tools & Diagnostics Analyst here at Morgan Stanley. It's my pleasure to host Maravai this morning, and we have Carl Hull and Kevin Herde from the company. So thank you both for joining us.

Questions & Answers

Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Maybe, Carl, just to kick things off, we'll get right into the weeds. Everyone knows who you are. So look, I mean, on the COVID side of things, clearly, you derisked the guide recently said it at $200 million to $300 million. But even at that midpoint, if you assume $0.30 per dose, that's about 830 million sort of annual doses. Why do you think that's a reasonable sort of like endemic run rate here? How are you thinking about upside or downside relative to that midpoint?

Carl W. Hull
Maravai LifeSciences Holdings, Inc. - Co-Founder, Chairman & CEO

Sure. Well, look, first, I put aside the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot